NRX Pharmaceuticals Reports Q3 2025 Financial Results with Increased Losses and First Revenue from Dura Medical Acquisition

NRX Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $5.9 million, compared to a loss of $1.6 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of approximately $29.0 million, an increase from a loss of $16.1 million for the same period in 2024. The company generated $242,000 in net patient service revenue during the quarter, marking its first revenue following the acquisition of Dura Medical, LLC on September 8, 2025. This revenue is expected to grow as Dura's operations are fully integrated and expanded.

The company's total assets increased significantly to $15.0 million as of September 30, 2025, up from $3.7 million at the end of 2024. This growth was primarily driven by the acquisition of Dura, which added cash, accounts receivable, and intangible assets to the balance sheet. However, total liabilities also rose to $40.8 million, up from $26.9 million, largely due to an increase in convertible notes payable and accrued interest, which amounted to $9.9 million as of the reporting date.

Strategically, NRX Pharmaceuticals has made significant advancements in its drug development pipeline. The company has filed an Abbreviated New Drug Application (ANDA) for its lead product, NRX-100, a preservative-free formulation of ketamine, and is seeking FDA approval for both NRX-100 and NRX-101, an oral combination therapy for bipolar depression. The company received Fast Track Designation from the FDA for NRX-100, which could expedite its path to market. Additionally, NRX-101 has shown promising results in clinical trials, and the company is exploring its use in conjunction with Transcranial Magnetic Stimulation (TMS) therapy.

Operationally, NRX Pharmaceuticals has expanded its clinical footprint through the acquisition of Dura and a minority interest in Cohen & Associates, enhancing its service offerings in interventional psychiatry. The company is also actively pursuing additional acquisitions to further grow its network. As of September 30, 2025, the company had 28,097,627 shares of common stock outstanding and reported a working capital deficit of $28.6 million. Looking ahead, management anticipates continued operating losses as it integrates Dura and seeks additional financing to support its clinical activities and product development.